On September 28, 2026 FDA said it intends to evaluate changes to the PMTA regulatory framework, "including through initiation of new rulemaking to replace the current framework." For manufacturers who have spent years building premarket tobacco product applications around the 2021 rule, the obvious question is whether to slow down and wait for whatever replaces it.
Our answer, from what the documents say, is no. FDA has announced an intention, not a proposal, and it says it will keep reviewing applications in accordance with the statutory requirements in the meantime. The core of what an application must say about its ingredients comes from the Tobacco Control Act itself, which no rule can rewrite. This post sets out what the announcement does and does not say, what today's rule asks about every ingredient, and what to keep collecting from your nicotine supplier while the framework is under review. Every source cited here was checked on October 1, 2026.
What FDA Actually Announced
The announcement is a short news release, not a rule, a proposed rule or guidance. In it, FDA says it is reviewing its experience implementing the PMTA rule, "as well as recent judicial developments, including a federal lawsuit filed in the U.S. District Court for the Northern District of Texas challenging the current regulatory framework."
The release gives three reasons for the review: "FDA's learned experience implementing the 2021 rule, the widespread development of an illicit and unregulated market, and the pace of new product introductions" (FDA). It says FDA believes "a modern framework that reflects current market realities and provides greater clarity and predictability is critical to maximizing the protection of public health."
What the release does not contain matters as much. It gives no timeline, names no docket, and says nothing about what a replacement would require. FDA commits only that "any future changes to the regulatory framework will be undertaken consistent with applicable law and with opportunities for public input." As of October 1, 2026 we found no advance notice, proposed rule or Federal Register docket for a replacement framework on the Federal Register.
What Has Not Changed
The 2021 rule is still the rule. It was published as Premarket Tobacco Product Applications and Recordkeeping Requirements, 86 FR 55300, on October 5, 2021 and took effect on November 4, 2021, and it is codified at 21 CFR Part 1114 (Federal Register). A statement that FDA intends to evaluate replacing a rule does not suspend it.
FDA says so directly. "In the meantime, FDA will continue to process PMTA submissions, conduct premarket reviews, and issue regulatory decisions on new tobacco products in accordance with the statutory requirements established by Congress," the release states. It adds that FDA remains committed to "applying the statutorily appropriate standard for the protection of public health (APPH) when reviewing PMTAs."
That standard comes from section 910(c)(2)(A) of the FD&C Act, 21 U.S.C. 387j, which requires FDA to deny an application where there is "a lack of a showing that permitting such tobacco product to be marketed would be appropriate for the protection of the public health." Under section 910(c)(4), it is judged against the risks and benefits to the population as a whole, including users and nonusers. A new rule could change how applicants show that. It cannot change the test.
The Ingredient Requirement Comes From the Statute
This is the point a supplier relationship turns on. The duty to describe what is in a product, and how it is made, is written into the Tobacco Control Act itself. Section 910(b)(1)(B) requires every PMTA to contain "a full statement of the components, ingredients, additives, and properties" of the product, and section 910(b)(1)(C) requires "a full description of the methods used in, and the facilities and controls used for, the manufacture" of it. Section 910(c)(2)(B) of the same statute also makes manufacturing a ground for denial: FDA must deny an application if the methods, facilities or controls used to make the product do not conform to the requirements of section 906(e), 21 U.S.C. 387f(e), the provision under which FDA sets tobacco product manufacturing practice requirements by regulation.
Our reading follows from that text, and it is ours rather than FDA's: whatever a replacement rule changes about format, depth or process, it cannot remove the statutory requirement to account for every ingredient and the controls behind it. The ingredient file you build with your nicotine supplier today is work that carries into any future framework. It is the same logic we applied to FDA's proposed manufacturing practice rule in TPMP Rule Stalled: Build to the Standard Anyway.
What Today's Rule Asks About Each Ingredient
Under the current rule, nicotine in a pouch or an e-liquid is an ingredient other than tobacco, and 21 CFR 1114.7 requires the application to give, for each one:
- the IUPAC chemical name and common name
- the CAS number or FDA Unique Ingredient Identifier
- the ingredient's function
- the quantity in the product, with ranges or means and acceptance limits
- "the specification(s) (including purity or grade and supplier)"
The manufacturing section of the same regulation asks for a summary of the procedures used for "identifying and monitoring suppliers and the products supplied (including, for example, purchase controls and product acceptance activities)." That is where a buyer's supplier qualification work ends up in the application.
Missing pieces have consequences before any science is reviewed. Under 21 CFR 1114.27, FDA may refuse to accept an application that is "not administratively complete" and may refuse to file one that "does not contain sufficient information required by section 910(b)(1)" to permit a substantive review. Our earlier post on 21 CFR 1114 and 1107 goes through these requirements from the supplier's side.
FDA's Faster Review Rewards Complete Applications
FDA has already changed how it processes applications this year, and those changes reward a complete file. In a statement on May 7, 2026, CTP's Acting Director said there "is no longer a queue for applications pending Acceptance Review," and that a PMTA will "almost immediately enter the first phase of application review" on receipt.
The same statement says CTP has realized efficiencies in filing review for nicotine pouch and ENDS applications over the past year, and that where some products in a submission can receive marketing granted orders while others need more information, they "are being reviewed separately where appropriate." It also describes a process for expedited review of certain supplemental PMTAs as work in progress: "CTP is working on" it, in the statement's words.
Faster gates help only applicants who clear them. An application that arrives quickly at acceptance and filing review and is then refused for a missing specification has lost time, not saved it. For pouch makers, FDA's pilot experience points the same way: the May statement says that during scientific review FDA asked applicants for information "that had been omitted from the PMTA but is needed to complete scientific review." We covered what the pilot's end means for pouch applications in FDA's Nicotine Pouch PMTA Pilot Is Closed to New Products.
What to Keep Collecting From Your Nicotine Supplier
None of the following depends on the outcome of FDA's review. The first two items are lines of 21 CFR 1114.7 as it stands today; the others are the supplier records that support them and the supplier-monitoring summary the same regulation asks for.
- Identity. The IUPAC and common name and the CAS number for the exact nicotine form, whether freebase or a specific salt.
- Specification. A written specification with the purity or grade and the acceptance limits your product is built to.
- Certificates of analysis for each lot, tied to that specification.
- Supplier identity. The supplier named in your file should be the one that actually makes or handles the material, not only the distributor on the invoice.
- Supplier controls. What your purchase controls and acceptance testing look like, so the procedure summary in your application describes something real.
If FDA eventually proposes a different framework, it will come with a comment period, and an applicant with a complete ingredient file will be in a position to read the proposal and comment on it rather than start from scratch. If you are assembling that file now, our pages for USP/EP grade nicotine and nicotine salts set out the grades and documents available, and you can request a quote or sample documentation for the form your product uses.
Frequently Asked Questions
Has FDA replaced the PMTA rule?
No. On September 28, 2026 FDA said it intends to evaluate changes, including new rulemaking to replace the framework, but it has not proposed anything. The 2021 rule at 21 CFR Part 1114 remains in effect, and FDA says it will keep processing PMTAs and issuing decisions in accordance with the statutory requirements established by Congress.
Should a manufacturer delay a PMTA until FDA's new framework is known?
Nothing FDA has published gives a reason to delay. FDA's release gives no timeline and says it will continue to process PMTAs and issue decisions under the statute. The statutory duty to give a full statement of ingredients in section 910(b)(1)(B) applies under any framework, so that work is not wasted.
What does a PMTA have to say about the nicotine in a product?
Under 21 CFR 1114.7, for each ingredient other than tobacco the application must give the chemical name, CAS number or UNII, function, quantity with acceptance limits, and the specification "including purity or grade and supplier." It must also summarize how the applicant identifies and monitors suppliers.
What lawsuit did FDA mention in its PMTA announcement?
FDA's release refers to "a federal lawsuit filed in the U.S. District Court for the Northern District of Texas challenging the current regulatory framework." The release lists it among the recent judicial developments FDA is reviewing, but it does not name the case or say what outcome FDA expects.